PharmaFocus Today – Page 16 – media

Signs Master Collaboration Agreement with Stella Pharma for the Commercialization of Boron Neutron Therapy Drugs

　　On August 12, Nanfang Finance News reported that China Biotechnology Services (08037.HK) issued a voluntary announcement stating that on August 11, 2026, the company entered into a legally binding master collaboration agreement with Stella Pharma Corporation for the development and commercialization in China of Steboronine®, the world’s first approved boron neutron therapy drug. The agreement is divided into two phases: development and commercialization. In the development phase, the company will be the exclusive agent to submit regulatory filings to the National Medical Products Administration (NMPA) to promote NMPA approval of Steboronine® for head and neck cancer and subsequent meningioma indications. In the commercialization phase, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. will act as the exclusive domestic agent, and the company or its designated entity will act as the exclusive general importer/distributor. The initial distribution rights will be valid for ten years after NMPA approval, automatically renewable for five ...
- Source: drugdu
- 364
- August 12, 2026
Medical device giant makes another move in spin-off.

According to recent foreign media reports, Solventum announced plans to spin off its Health Information Systems business as part of its portfolio optimization strategy. Image source: Latest Medical Device News on MassDevice Solventum was spun off from the former 3M healthcare business in 2024, and subsequently announced a massive $120 million restructuring plan in 2025. This spin-off marked the first phase of Solventum’s management’s business transformation strategy, with the goal of “building consensus and strengthening the foundation,” including establishing a new mission of “improving human health with better, smarter, and safer healthcare solutions.” In the second phase, Solventum will focus on strategic in-depth development, with 80% of revenue growth expected to come from five major areas: negative pressure wound therapy, intravenous catheter management, sterilization assurance, basic repair products, and revenue cycle management. This spin-off is the latest step in Solventum’s three-phase transformation strategy, aimed at maximizing shareholder value and preparing ...
- Source: drugdu
- 356
- August 12, 2026
Johnson & Johnson veterans lead the way as ICL giant embarks on its second growth curve.

According to recent foreign media reports, Staar Surgical announced the appointment of Warren Foust as the company’s new president and CEO. Image source: Latest Medical Device News on MassDevice Founded in 1982, Staar Surgical focuses on the ophthalmology sector. According to data from Tidus Medical Devices, the company currently has 75 products on the market in the United States and 5 products on the market in China. Its core product pipeline is the Evo implantable collagen lens (ICL) pipeline. Its newly appointed President and CEO, Foust, joined the company in April 2023 as Chief Operating Officer and will assume the title of President in March 2025. During his tenure at Staar, he was responsible for research and development, global sales, marketing, manufacturing, and operations. The company stated that he led the company to a successful operational restructuring and a return to profitable growth. Foust is a seasoned veteran of the ...
- Source: drugdu
- 352
- August 12, 2026
A Milestone in Pediatric Traditional Chinese Medicine Innovation! Jichuan Pharmaceutical’s Pediatric Laxative Granules Fill a Gap

Recently, Jichuan Pharmaceutical’s independently developed Class 1.1 innovative traditional Chinese medicine, Xiaotongbian Granules ( Pediatric Constipation Relief Granules) , officially received marketing approval from the National Medical Products Administration. This product fills the gap in the domestic market for traditional Chinese medicine specifically for children’s constipation , enriches the company’s product portfolio, and enhances its core competitiveness in the pediatric field. 01 Classic prescriptions from renowned doctors benefit a large number of children suffering from constipation Pediatric Constipation Relief Granules are the first innovative traditional Chinese medicine (TCM) drug approved for use in children under the new regulations and guidelines for innovative TCM drugs. It is the first innovative demonstration product in this field , filling a gap in domestic TCM treatments specifically for childhood constipation. The prescription originates from the clinical experience of pediatric expert Chen Yonghui (Capital Children’s Medical Center, Capital Medical University), and clinical trials have verified ...
- Source: drugdu
- 159
- August 10, 2026
Vonoprazan Fumarate Tablets Receive Drug Registration Certificate

On August 7th, Huahai Pharmaceutical(600521) issued an announcement stating that the company recently received the “Drug Registration Certificate” for vonoprazan fumarate tablets issued by the National Medical Products Administration. The drug is a tablet, with specifications of 20mg and 10mg, and is registered as a Class 4 chemical drug. Vonoprazan fumarate tablets are used for reflux esophagitis and can be used in combination with appropriate antibiotics to eradicate Helicobacter pylori. According to data from Menet.com, the domestic market sales of this drug are projected to reach approximately RMB 282 million in the first quarter of 2026. The company’s R&D investment in the vonoprazan fumarate tablets project is approximately RMB 4.22 million. In the first quarter of 2026, Huahai Pharmaceutical achieved revenue of 2.335 billion yuan and net profit attributable to the parent company of 404 million yuan. https://finance.eastmoney.com/a/202608073835322537.html
- Source: drugdu
- 154
- August 10, 2026
Lenvatinib Mesylate Capsules Receive Drug Registration Certificate

Nanfang Finance News, August 7th – Lu Kang PharmaceuticalThe company announced that it has received a Drug Registration Certificate for Lenvatinib Mesylate Capsules issued by the National Medical Products Administration. This product is used to treat patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy. https://finance.eastmoney.com/a/202608073835336556.html
- Source: drugdu
- 151
- August 10, 2026
Loxoprofen Sodium Patch Receives Drug Registration Certificate

　　Fuyuan Pharmaceutical(601089.SH) announced that it has received a Drug Registration Certificate for Loxoprofen Sodium Patches from the National Medical Products Administration, approving the production of the drug. This drug is used for anti-inflammatory and analgesic purposes for osteoarthritis, muscle pain, and swelling or pain caused by trauma. As of the date of the announcement, the company’s cumulative R&D investment in this drug is RMB 11.7065 million. Sales of Loxoprofen Sodium Patches in China’s three major terminal markets and six major markets are projected to reach approximately RMB 901 million by 2025. https://finance.eastmoney.com/a/202608073835312137.html
- Source: drugdu
- 170
- August 10, 2026
Subsidiary obtains drug registration certificate for injectable multivitamins (12)

　　Wei Xinkang(603676.SH) announced that its wholly-owned subsidiary, Baiyi Pharmaceutical, received approval from the National Medical Products Administration for injectable multivitamins .(12) Drug Registration Certificate. This drug is a Class 4 chemical drug and is considered to have passed the consistency evaluation. In 2025, the sales of this drug in domestic public medical institutions reached RMB 1.601 billion, and the cumulative R&D investment as of the end of July 2026 was RMB 11.3139 million. https://finance.eastmoney.com/a/202608073835199693.html
- Source: drugdu
- 156
- August 10, 2026
its stock price has shrunk by 90% from its issue price, and although it has finally received approval for its first product, the market landscape has already changed.

Kang Le Guardian (i.e., *ST Kang Le)(BJ920575, stock price 4.71 yuan, market value 1.323 billion yuan) has finally ushered in its long-awaited first commercial product. Delivery letter of drug approval certificate published by the National Medical Products Administration on July 30Information shows that the trivalent human papillomavirus vaccine from Health Guard (Kunming) Biotechnology Co., Ltd.(Escherichia coli) has been approved, with approval number S20260057, and approval date July 28. This product covers HPV types 16, 18, and 58. KangLeGuardian had been waiting for this moment for far too long. In March 2023, KangLeGuardian went public on the Beijing Stock Exchange with an issue price of 42 yuan per share, becoming the first HPV stock on the Beijing Stock Exchange. That was also a high point for HPV vaccines —more than 58 million doses were administered in China throughout the year, and HPV vaccines became the vaccine category with the largest increase ...
- Source: drugdu
- 214
- August 4, 2026
China’s first generic tiotropium bromide inhalation spray approved.

China Securities Intelligent Finance News: BrightGene Pharmaceutical(688166) announced on the evening of July 31 that its holding subsidiary, Aitemei (Suzhou) Pharmaceutical Technology Co., Ltd., recently received a Drug Registration Certificate for Tiotropium Bromide Inhalation Spray issued by the National Medical Products Administration. The specification is 60 sprays per bottle, the registration category is chemical drug category 4, and the drug approval number is valid until July 27, 2031. The announcement indicates that this drug is suitable for maintenance treatment of chronic obstructive pulmonary disease (COPD) and related dyspnea, and can reduce acute exacerbations of COPD. The original manufacturer is Boehringer Ingelheim, and currently only the original imported version is available on the market. The National Medical Products Administration (NMPA) website shows that there are currently no generic versions of this drug available in China, making Boehringer Ingelheim the first company to receive approval for its market launch in the country. ...
- Source: drugdu
- 200
- August 4, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.